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1. Introduction 
Coronary artery disease is the highest contributor to morbidity and premature death in the 
developed world (Nabel, 2003; Fuster et al., 1992; Melo et al., 2004). Cardiac function is 
compromised in patients that survive an initial ischemic event and this progressive 
myocardial impairment leads to heart failure (Liu et al., 2007; Sugamura and Keaney, 2011; 
Jessup and Brozena, 2003). High levels of reactive oxygen species (ROS) contribute to the 
process of disease progression in both myocardial ischemia and in models of heart failure. 
ROS play a role in short term responses (stunning and arrhythmias) as well as long term 
responses (infarction) to ischemia with reperfusion. The primary source of ROS in 
myocardial ischemia is from mitochondria of cardiac cells with additional ROS arising from 
neutrophils that infiltrate ischemic regions (Sugamura and Keaney, 2011). There have been 
promising preclinical studies employing some antioxidant enzymes but there are no 
currently accepted clinical applications of these enzymes for myocardial ischemia (Downey, 
1990; Zweier et al., 1987, Otani et al., 1986; Papaharalambus and Griendling, 2007; 
Vivekananthan et al., 2003). It is likely that the responses in the ischemic heart are more 
complicated than was initially realized and other  antioxidant based strategies have to be 
developed. Our work has focused on two protective agents that act to prevent the 
detrimental effects of oxidative stress in the ischemic heart. The first cardio-protectant is  
methionine methionine sulfoxide reductase A (MsrA), a member of the Msr family of 
enzymes. The other major enzyme in the Msr family is MsrB and these two enzymes differ 
in their substrate stereo-specificity. The Msr family of enzymes  can protect cells in two 
ways: 1) by repairing oxidative damage to critical methionine  (Met) residues in proteins 
which have been oxidized to methionine sulfoxide (met(o)), and 2) by functioning as part of 
an ROS scavenger system in which Met residues in proteins function as catalytic 
antioxidants. MsrA has been studied in most detail and shown to protect bacterial and 
animal cells against oxidative damage (for review see Weissbach et al., 2005). The studies 
with MsrA led to investigations with the drug sulindac, a known non-steroidal anti-
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inflammatory drug (NSAID), that is a substrate for the Msr system (Etienne et al. 2003; 
Brunell et al. 2011). Sulindac protects the heart against ischemic infarction through a newly 
described activity as a pharmacological preconditioning agent (Moench et al., 2009). 
2. Antioxidant therapies and oxidative stress in heart disease 
ROS normally produced as a by-product of the electron transport chain are now considered 
to be a major factor in aging and age related diseases (Bokov et al., 2004). In the heart high 
levels of ROS have been implicated in both ischemic damage and in the progression of heart 
failure (Giordano, 2005). Preclinical studies for ischemic heart disease employing 
antioxidants although still at an early stage have shown some promise (Sugamura and 
Keaney, 2011; Bolli et al., 2004; Cannon, 2005). For example heme oxygenase -1 (HO-1) based 
gene therapy has been proposed as a therapeutic strategy for ischemic heart disease because 
the enzyme has a clear antioxidant capacity (Liu et al., 2007). In addition, the products of 
heme metabolism, carbon monoxide and bilirubin have been reported to possess cyto-
protective properties (Poss and Tonegawa, 1997; Stocker et al., 1987). Cardiac expression of 
HO-1 increased Akt phosphorylation and decreased infarct size in a mouse model of 
ischemia/reperfusion. Knockdown of the bilirubin producing enzyme biliverdin reductase 
increases apoptosis of cardiac cells subjected to hypoxia /re-oxygenation and decreases Akt 
phosphorylation. Thus the protection afforded by HO-1 involves activation of Akt that is 
dependent upon biliverdin reductase (Pachori et al., 2007). 
Other antioxidant enzymes that have shown potential for protection against ischemic 
damage include extracellular superoxide dismutase (EC-SOD-1), thioredoxin (Trx), and 
glutathione peroxidase (GSHPx) (Agrawal et al., 2004; Yoshida et al., 1996; Turoczi et al., 
2003; Maulik et al., 1999). Gene transfer of EC-SOD-1 by direct intra myocardial injection 
using an AAV vector resulted in high level cardio-protection in rats at 7 days following 
ischemia and reperfusion injury (Agrawal et al., 2004). Using the rat working heart model of 
transient global ischemia it has been shown that thioredoxin is substantially decreased, 
whereas preconditioning by non-lethal ischemia elicited up-regulation of Trx expression 
and induced tolerance against severe ischemic stress (Turoczi et al., 2003). Likewise Trx-1 
overexpressing mice were found to have reduced myocardial infarct size after a prolonged 
ischemia episode (Turoczi et al., 2003). Glutathione peroxidase (GSHPx) knockout mice have 
been shown to be more susceptible to ischemic damage than wild type mice, whereas 
GSHPx overexpressing mice are protected against myocardial ischemic damage (Maulik et 
al., 1999). 
In models of heart failure the contribution of ROS has been demonstrated to contribute to 
hypertrophic adaptations and to apoptosis (Li et al., 2002; Kwon et al., 2003; Giordano, 
2005). Cardiac hypertrophy can be either a physiological adaptation or part of the pathology 
that ultimately progresses to heart failure (Giordano, 2005). ROS signaling has been 
implicated in hypertrophic growth associated activation of MAPKs (Sabri et al., 2003; Ghosh 
et al., 2003). For example, inhibition of ROS by chemical antioxidants prevents A-II induced 
hypertrophy (Nakamura et al., 1998; Delbosc et al., 2002). ROS induced alterations in 
transcription factor activation has been reported in cardiac hypertrophy and several studies 
point to a role for ROS in the induced chromatin remodeling in the failing heart (Giordano, 
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2005). ASK-1 provides a link between oxidative stress and hypertrophy since following 
activation by ROS, Ask1 induces activation of p38-MAPK and JNK causing apoptosis 
(Izumiya et al., 2003). The apoptotic process is central to heart failure and the effect of ROS 
on apoptosis is dependent upon the levels of ROS produced (Kwon et al., 2003). It is clear 
that high levels of ROS will elicit apoptosis via JNK and p38-MAPKs, whereas low levels of 
ROS can function as signaling molecules and help to protect cells under certain 
physiological conditions, as is the case with ischemic preconditioning discussed below 
(Kwon et al., 2003; Das, 2001; Hool, 2006; Murry et al., 1986; Yellon and Downey, 2002; Bolli, 
2000).  
3. MsrA and cellular protection 
Of the amino acids in proteins that can be oxidized by ROS, Met is one of the most sensitive, 
being converted to methionine sulfoxide (Met(o)) (Weissbach et al., 2005). Since the sulfur in 
Met(o) has a chiral center this chemical oxidation yields a mixture of the R and S epimers, 
Met-R-(o) and Met-S-(o), as shown in Figure 1.  
 
Fig. 1. Products of methionine oxidation. 
Further oxidation of Met(o), leads to the formation of methionine sulfone, which has been 
detected in proteins at very low levels and its significance is not known. As also shown in 
Figure 1 Met(o) in proteins can be reduced back to Met by the Msr enzymes. The two main 
members are MsrA and MsrB, which reduce the S epimer and R epimer of Met(o), 
respectively. It is now known that there is one msrA gene in mammalian cells and three 
msrB genes, the latter referred to as MsrB1, 2 and 3 (Vougier et al., 2003; Kim and 
Gladyshev, 2004; Hansel et al., 2005). 
Although MsrA was first discovered more than 30 years ago in studies on protein synthesis in 
bacteria (Brot et al.,1981),  its important role in protecting cells against oxidative damage only 
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became apparent in the early 1990's after the MsrA gene was cloned from both Escherichia coli 
and bovine liver (Rahman et al., 1992; Moskovitz et al., 1996). When MsrA was knocked out in 
E. coli the organism grew normally, but was extremely sensitive to oxidizing agents 
(Moskovitz et al., 1996, St. John et al., 2001). Since then there have been several studies 
demonstrating that over-expressing MsrA in animal cells can protect them against oxidative 
damage (Moskovitz et al., 1998; Kantorow et al., 2004; Yermolaieva et al., 2000) and lead to 
extended life span in both flies and yeast (Ruan et al., 2002, Koc et al., 2004) . As one example 
in cells in culture, over-expression of MsrA by transfection of PC12 cells with an adenovirus 
vector encoding MsrA resulted in a greater tolerance for oxidative stress following hypoxia 
with re-oxygenation (Yermolaieva et al., 2004). MsrA overexpressing cells showed significantly 
lower levels of ROS and apoptosis than cells infected with no virus or control plain virus. In 
Drosophila, overexpression of MsrA was protective against oxidative stress. When the MsrA 
transgene was over-expressed the flies were found to be more resistant to paraquat induced 
oxidative stress and  when the MsrA was predominantly expressed in the nervous system 
there was a dramatic increase in lifespan (Ruan et al., 2002) (Figure 2).  
 
Fig. 2. Extension of life span of flies by neuronal expression of MsrA.                    and O-O, 
control flies;               MsrA overexpressing flies. From Ruan et al., 2001. 
To determine the effect of MsrA in protecting against hypoxia/re-oxygenation damage in 
cardiac cells we transduced primary rat cardiac myocytes with an MsrA encoding 
adenovirus (Prentice et al., 2008). In cells over-expressing MsrA, apoptotic cell death 
resulting from hypoxia/re-oxygenation was decreased by greater than 45% relative to cells 
expressing control virus (Figure 3). 
The protection of cardiac myocytes in culture against hypoxia/re-oxygenation stress by 
MsrA over-expression points to MsrA as a potential therapeutic agent for treatment of 
ischemic heart disease (Prentice et al., 2008). 
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Fig. 3. Protection of cardiac myocytes following hypoxia /reoxygenation by sulindac as 
measured by levels of LDH released. **p<0.01 vs air control virus (N=6). *p<0.01 vs 
hypoxia/reoxygenation control virus (N=6). From Prentice et al. 2008 
In contrast, knocking out MsrA makes mammalian cells more sensitive to oxidative stress. 
MsrA and MsrB knockout in lens and retinal cells make these cells more sensitive to 
oxidation (Marchetti et al., 2006; Kantorow et al., 2004). There have been reports on MsrA 
knockout mice in which it is clear that these animals are very sensitive to increased oxygen 
tension, although there is conflicting data on their life span and the presence of a 
neurological defect (Moskovitz et al., 2001, Salmon et al., 2009). The MsrA knockout mice 
also have been reported to contain increased brain dopamine levels at 6 and 12 months of 
age perhaps because of enhanced dopamine synthesis, but at 16 months the mice showed 
reduced dopamine levels compared to younger animals (Oien et al., 2008). Experiments 
addressing physiological  alterations in the heart resulting from a loss of MsrA have been 
carried out using the MsrA-/- knock-out mouse model (Nan et al., 2010). Under normal 
non-stressed conditions cellular contractility and cardiac function are not altered in the 
MsrA-/- mice. However when cardiac cells are stressed with high stimulation frequencies 
(2Hz) or with hydrogen peroxide a significant modulation in cardiac contractility is seen 
(Figure 4). 
There were corresponding changes in calcium transients in MsrA-/- cardiac myocytes 
treated with 2 Hz stimulation or with hydrogen peroxide. EM analysis also showed 
significant swelling of the mitochondria in MsrA-/-mouse hearts and protein oxidation 
levels in MsrA-/- mouse hearts were higher than those of wild type controls (Nan et al., 
2010). Similar morphological changes in mitochondria have previously been reported in 
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diseased hearts either from dilated cardiomyopathy or from myocardial ischemia and such 
ultrastructural changes have been associated with aging and senescence (Trillo et al., 1978; 
Schaper et al., 1991; Scholz et al., 1994; Terman et al., 2004) . This study indicates that there is a 
serious defect in mitochondrial function in the hearts of MsrA-/- mice resulting in 
compromised contractility and cellular dysfunction, especially under stress (Nan et al., 2010). 
 
Fig. 4. MsrA knockout (MsrA -/-) mice show decreased contractility when stressed by high 
frequency (2Hz) or with hydrogen peroxide treatment. (a) Raw traces of sarcomere 
contraction under 0.5 Hz or 2 Hz stimulation. (b) Shortening amplitude with 0.5Hz and 2 
Hz. (c) Raw traces of sarcomere contraction with or without H2O2 treatment. (d) Shortening 
amplitude in cardiomycytes with or without H2O2 treatment. Data are presented as 
mean+/- SD and obtained from 25-30 cells (3 mice per group); *p<0.05. From Nan et al.,2010 
Previous studies had demonstrated that approximately 75% of MsrA was targeted to the 
cytosol and 25% to the mitochondria (Kim et al., 2010; Vougier et al., 2003). A recent study 
by Zhao et al., (2011) examined the role of MsrA in different cellular compartments and 
assessed whether the enzyme would protect against ischemia reperfusion damage in the 
Langendorff heart. The investigators employed transgenic mice that overexpressed MsrA 
either in the myocardium or in the cytosol. A surprising finding was that mitochondrial 
targeted MsrA was not protective in the Langendorff model against ischemia/reperfusion. 
By contrast the cytoplasmic form of MsrA was protective, but the effect was dependent on 
myristoylation of the enzymes. It was proposed that myristoylation may facilitate targeting 
of MsrA to its protein targets to elicit myocardial protection. 
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4. Dual function of the Msr system 
It was initially thought that the main role of the Msr system was to repair oxidative 
damage to proteins in which critical met residues were oxidized to met(o). There has been 
ample evidence that this is an important function of the Msr system. Once again most of 
the studies have been done with MsrA. There are now a long list of proteins and peptides 
whose activities are altered by Met oxidation in vitro (Brot and Weissbach, 2000) and 
many examples of how the activity can be restored in part by MsrA. One of the first 
examples was the oxidation of Met 358 in alpha one proteinase inhibitor. This enzyme, 
which may play a role in emphysema, loses its protease inhibitor activity when this Met is 
oxidized and the activity can be restored by MsrA (Abrams et al., 1981). More recently, 
oxidation of met residues in proteins has been reported to cause a major change in 
function of a number of proteins. As examples, in a shaker ShC/B voltage gated 
potassium channel, when a key methionine residue in the inactivation ball is oxidized, the 
channel activation is slowed down, but this process is reversed by MsrA (Ciorba et al., 
1997). A methionine in the C terminus of calmodulin is selectively oxidized by hydrogen 
peroxide (Yao et al., 1996). The extent of oxidative modification was found to correlate 
with loss of CaM dependent activation of the plasma membrane Ca-ATPase. The protein 
calcium/calmodulin (Ca2+ CaM) dependent protein kinase II (CamKII) links increases in 
intracellular calcium to activation of ion channels, transcriptional responses and cell fate 
decisions. A recent study analyzing the role of CaMKII in heart demonstrated that 
CamKII is a common signaling point for increased apoptosis regulated by ROS, 
catecholamine signaling and angiotensin-II (Ang-II) (Erickson et al., 2008). MsrA was 
found to be essential for reversing CaMKII methionine oxidation in the ischemic heart in 
vivo. 
However, Levine et al. (1996), in their studies on glutamine synthetase,  first introduced the 
important concept that the Msr system could be part of a ROS scavenger mechanism. In this 
mechanism, Met residues in proteins, even when not at an active site, can be oxidized to 
Met(o) and in the process  destroy a ROS molecule. The Msr system could then regenerate 
the Met which could once again be oxidized by an ROS molecule. Thus, the Met residues in 
proteins could function as catalytic anti-oxidants dependent on the Msr system. There are 
now several cell culture studies to support this mechanism. In PC12 cells over-expression of 
MsrA lowers the level of ROS in the cells and in lens and retinal cells knocking out of MsrA 
leads to higher ROS levels (Yermolaieva et al., 2004; Marchetti et al., 2006). 
5. Sulindac is a substrate for the Msr enzymes 
If Met residues in proteins could function as catalytic anti-oxidants based on the Msr system 
it seemed reasonable that other substrates of the Msr enzymes might function in cells as 
catalytic anti-oxidants. One such compound that was shown to be a substrate for MsrA was 
sulindac, a known NSAID (Duggan et al., 1977). The structure of sulindac and its 
metabolites is shown in Figure 5. Sulindac is a prodrug that must be reduced to sulindac 
sulfide which is the active NSAID. Since sulindac is also a mixture of the R and S epimers 
the metabolism of both epimers has been recently elucidated as shown in Figure 5 (Brunell 
et al., 2011).  
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Fig. 5. Metabolism of the sulindac epimers. The R and S epimers of sulindac can be oxidized 
to sulindac sulfone and reduced to sulindac sulfide. From Brunell et al. 2011. 
The reduction of the S epimer is catalyzed by MsrA and as seen in Figure 6, the R epimer 
is reduced by an enzyme in liver that has the properties of MsrB (Brunell et al., 2011). 
Sulindac can also induce the P450 system  and be oxidized by the P450 system to sulindac 
sulfone (Ciolino et al., 2008; Brunell et al., 2011). Sulindac sulfone is not an NSAID and is 
not a substrate for the Msr system. It seemed reasonable to see whether sulindac might 
function as a catalytic anti-oxidant and protect cells against oxidative damage. In our 
preliminary experiments several normal cells were not protected by sulindac after 
exposure to oxidative stress, but normal lung cells were (Marchetti et al., 2009). An 
unexpected finding was that under similar conditions colon and lung cancer cell lines, 
that were pretreated with sulindac, showed enhanced killing of these cells when exposed 
to oxidative stress. The protective effect of sulindac with normal lung cells and the 
enhanced killing with the cancer cell lines was not due to the NSAID activity of sulindac 
or did it involve the Msr system since sulindac sulfone gave a similar effect as sulindac 
(Marchetti et al., 2009). As will be shown below, using cardiac cells, the protection seen 
against oxidative damage by sulindac is by an ischemic preconditioning mechanism 
(Moench et al., 2009). 
6. Sulindac causes cardiac protection by ischemic preconditioning 
Pharmacological preconditioning has been reported to occur in response to certain drugs 
that mimic the effects of ischemic preconditioning, a process known to elicit protective 
responses against myocardial stunning and infarction. Ischemic preconditioning has been 
reported to elicit an early phase of protection from 0-2 hours after the initial stimulus as well 
as a late phase of preconditioning from 1 -7 days after ischemia (Kuzuya et al., 1993; Marber 
et al., 1993; Bolli, 2000). A number of pharmacological agents can induce preconditioning 
include cytokines, opioids, adenosine, nitric oxide donors and bradykinin although these 
agents may differ in their capacity to protect against infarction, stunning or both infarction 
and stunning (Bolli, 2000). 
The mechanisms of early preconditioning have been shown to involve NO activation of 
soluble guanylyl cyclase (GC), activation of PKG and opening of mitochondrial ATP 
dependent potassium channels (K-ATP channels) (Costa et al., 2008). Subsequent generation 
of ROS from the mitochondrion results in activation of PKC (Costa et al., 2008; Baines et al., 
1997; Tritto et al., 1997). The mediation events of early preconditioning have been shown to 
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involve inhibition of the formation of the mitochondrial permeability transition pore, and in 
some cases, such as with protection by adenosine, this mediation involves PKC activation 
and PKG activation (Costa et al., 2008). 
Late preconditioning is triggered through the action of NO as well as through ROS release 
(Bolli, 2001; Bolli et al., 1997). PKC epsilon translocates to the membrane fraction which is 
then followed by activation of the MAPK signaling cascade (Xuan et al., 2007). 
Downstream events include phosphorylation of STAT1/3 and activation of STAT 
dependent genes which include the COX-2 gene. Other events that mediate late 
preconditioning include NO release (through a PKG dependent mechanisms and opening 
of mitochondrial K(ATP) channels (Bernardo et al., 1999; Ockaili et al., 1999). It has been 
reported that the NO that mediates late preconditioning is derived from inducible NOS 
(iNOS). Some of the components involved in ischemic preconditioning are summarized in 
Figure 6. 
 
Fig. 6. Overview of mechanisms of preconditioning involving PKC, iNOS and mitochondrial 
pro-survival events. 
In investigating the role of sulindac as a protective agent we examined the effect of sulindac 
treatment on neonatal rat cardiac myocytes subjected to hypoxia and re-oxygenation and in 
an ex vivo Langendorff model of myocardial ischemia (Moench et al., 2009). We 
demonstrated that sulindac (<100uM) afforded high level protection of cardiac myocytes 
subjected to hypoxia and re-oxygenation (Figure 7). 
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Fig. 7. Sulindac protects cardiac myocytes against oxidative damage. Cardiac myocytes were 
exposed to hypoxia for 24 h and reoxygenation for 20 h to elicit oxidative stress in the 
presence or absence of sulindac. Lactate dehydrogenase (LDH) levels (shown as absorbance 
units) were measured in the media as an index of cell death and levels were compared to 
those for untreated myocytes (*,P<0.05 vs. no drug; n=6, **, p<0.01 vs. no drug; n=6). From 
Moench et al., 2009. 
In the Langendorff experiments rats were fed sulindac for 2 days prior to removal of the 
heart which was then subjected to 45 minutes of ischemia followed by 2 hours of 
reperfusion with oxygenated buffer (Figure 8). Sulindac was highly protective against 
myocardial ischemia through mechanisms that did not involve Cox inhibition or its anti-
inflammatory capacity.  
As an example, the NSAID ibuprofen was not capable of protecting against no flow 
ischemia in the Langendorff model. Furthermore the oxidized form of sulindac, sulindac 
sulfone, which as mentioned,  is not an NSAID was found to give significant protection 
against ischemic damage. Through the use of a PKC inhibitor and a ROS scavenging agent 
we have demonstrated that sulindac protects the heart from ischemic stress by acting as a 
pharmacological preconditioning agent. PKC is known to mediate preconditioning either by 
ischemia or by pharmacological agents and in our studies daily administration of the PKC 
blocker chelerytherine removed the protection provided by sulindac (Figure 8). The  
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Fig. 8. Effect of feeding sulindac  on infarct size after ischemia and reperfusion as measured by 
TTC staining. Where indicated  the PKC inhibitor chelerythrine was administered to the 
animals. (A) Graph represents percent of heart that was infarcted (*, P<0.01 compared to no-
drug control; n=4, **., P<0.01 compared to sulindac treated hearts; n=4). (B) Representative 
sections from langendorff hearts subjected to 45 min ischemia and 2h reperfusion showing 
viable tissue (red) and infarcted tissue (white). From Moench et al. 2009. 
mechanism of sulindac protection appear to involve the following steps: 1) ROS increase as 
a trigger for subsequent signaling, 2) signaling through PKC, 3) induction of expression of 
downstream gene products including iNOS and Hsp27. Ongoing experiments are 
addressing more specifically the PKC isoforms involved in the protective action of sulindac, 
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As noted above, a remarkable property of sulindac is its ability to kill cancer cells in the 
presence of an oxidant while being able to protect certain normal cells through 
pharmacological preconditioning (Marchetti et al., 2009; Moench et al., 2009). It is notable 
that a similar phenomenon has recently been reported for the PDE-5 inhibitor sildenafil (Das 
et al., 2010). This drug was found to enhance the doxorubicin induced killing of prostate 
cancer cells while also protecting cardiac cells from doxorubicin induced cardiomyopathy. 
The mechanisms of doxorubicin induced killing of cancer cells involved enhanced 
generation of ROS (Das et al., 2010). It will be important in future studies to determine the 
ways by which  sulindac and sildenafil are capable of modifying the effects of increased 
ROS  in cardiac cells leading to cell survival while also sensitizing cancer cells to oxidative 
stress resulting in killing of these cells. 
7. Final thoughts 
Antioxidant based approaches have already shown potential as strategies for the 
treatment of heart disease and interventions that increase intracellular MsrA have been 
protective in cardiac cells either through preventing an increase in ROS levels or through 
modifying important protein targets. Future therapies that are likely to be successful 
using the MsrA system may need to focus on activation of endogenous MsrA through 
applying pharmacological activators of MsrA identified from library screening 
procedures. A recent study by Minniti and colleagues (Minniti et al., 2009) noted that the 
MsrA promoter is activated by FOXO3A (De Luca et al., 2010). On the basis of this finding 
a potentially powerful strategy for increasing MsrA expression would involve transfer of 
FOXO3A protein into cells as a highly permeable TAT-FOXO3A-fusion protein which in 
turn would translocate to the nucleus and activate the MsrA gene. A simpler and more 
direct avenue for increasing MsrA levels would be to transfer a TAT-MsrA fusion protein 
directly into cells.  
Regarding sulindac, although there has been serious concern that NSAIDs cause cardiac 
damage, here we demonstrate that at the concentrations used sulindac can, in fact, afford 
cardiac protection through preconditioning mechanisms. This is very likely due to the fact 
that a substantially lower dose is needed for preconditioning than was previously employed 
for anti-inflammatory applications. Future approaches based on the preconditioning 
properties of sulindac may involve metabolites or derivatives that are not NSAIDs and do 
not inhibit COX 1 or COX2. One such metabolite, sulindac sulfone, has been shown to be 
lacking in NSAID activity but has the cardiac protectant activity (Moench et al., 2009). As 
there is a very significant need clinically for effective cardioprotective agents our recent 
studies on cell culture and in vivo models showing high level cardiac protection by  MsrA 
and by sulindac may point to the future application of these agents as important therapeutic 
breakthroughs for heart disease. 
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